BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2022 Earnings Call Transcript

Charlie Gayer: I will take the first question, Brian. Yes. So, it’s really much more of the first thing you said. So, as we are expanding to less experienced prescribers within the HAE space. It worked to get any drug, whether it’s ORLADEYO any other HAE therapy approved by insurers. It’s not a contracting issue. It’s really about providing all the information, the lab test, the clinical history, the complete information that payers want to see before approving any treatment for HAE. And so that’s a big part of the team expansion that we have described, so we have more people out there to help with this process to get patients to paid therapy. And it’s really about having a very complete prior authorization and reauthorization to make sure that we help them give all the information that the payers need.

So, I am actually with what I am seeing, I am confident that we are going to make great improvement in this ratio of paid to free product, it’s not all going to be in Q1. It is going to be a year-long process. But I think we are very much on the right track.

Jon Stonehouse: Helen, do you want to take the 10013.

Helen Thackray: Yes. So, on your question on 10013, so this is the non-clinical information we are reporting today, this is an ongoing study, and so we still have more to learn here. We always are in close touch with regulators over what’s going in €“ on what data comes in programs that’s non-clinical and clinical. We have deferred the higher dose levels in our healthy volunteer study, and so we learn more about this information, but we do still plan to go forward in patients that take the drug therapeutic range and patients understand there. What we are seeing is that as the non-clinical data informs your understanding of the range of exposures we expect it will have some delay in how fast, how high we go to the fast for dose sorry, how fast we go to the higher doses in patients in the study.

Charlie Gayer: And Brian, if I could just come back, I realize that probably didn’t answer part of your question, which is just on patient mix, it doesn’t have anything to do with the patient mix. It’s all about the others that I described just giving the doctors €“ or sorry, giving the plans or the information that they needed. Remember, half of our patients since launch have been patients switching from other prophy product. So, it’s really €“ it’s not about the patient.

Brian Abrahams: It’s really helpful. Thanks Charlie. Thanks Helen. Appreciate it.

Operator: The next question comes from Maury Raycroft of Jefferies. Please go ahead.

Maury Raycroft: Hi. Good morning and thanks for taking my questions. I was wondering for Quad AI later this week. If you can provide some preview around observed similarities or differences in treating pediatric HAE patients and remind what the sNDA timeline could look like? And how does the pediatric opportunity fit into your $1 billion peak sales estimate?